MAPT and Alzheimer disease: Liu and colleagues observed 1718 participants from Alzheimer’s Disease Neuroimaging Initiative (ADNI) and found significantly decreased Aβ42 and increased tau/p-tau levels in the CSF in the ε4 carriers, which appeared earlier than other biomarkers of AD [111].